Lung Cancer Update, Issue 3, 2016 (Video Program) - Video 9Antitumor activity and ongoing investigation of the third-generation EGFR TKIs olmutinib (BI 1482694) and ASP8273 for advanced EGFR mutation-positive NSCLC
1:46 minutes.
TRANSCRIPTION:
DR BLUMENSCHEIN: So they’re third-generation drugs. The olmutinib study was done I believe in Korea only, and the patients were T790M-positive. And it had a similar response rate to osimertinib, around 60% in that patient population and had duration of response of roughly 8 to 9 months. And it had the typical side effects of diarrhea, rash. I’m not sure where they’re going with this because you’re right, it is a hard space for another drug to break into without being markedly different, or showing activity, perhaps, in osimertinib-refractory patients. I do think they’re doing a Phase II study — actually, they completed accrual, ELUXA-1, where they were looking at this particular compound. And they’re looking at some other combinations or comparators in this population with this compound. But you're right, I think it’s going to be a difficult space to step into: (A) you’ve got to get the activity, and (B) you’ve got to have a reasonable toxicity profile that’s going to make a rationale for wanting to try the drug. DR LOVE: What about this agent ASP8273? DR BLUMENSCHEIN: We don’t have a lot of data on that. I think roughly 50-odd patients were treated on that particular study. It’s a Phase I study. And from what I took away from reading through the abstract and looking at the poster, there was a disease control rate of around 60%, but the response rate was more in the 30% to 40% range. Which wasn’t as robust as we saw with osimertinib or with the olmutinib, excuse me. |